Mesenchymal stem cell therapy for liver fibrosis.
Mesenchymal stem cell therapy for liver fibrosis.
复制标题
间充质干细胞治疗肝纤维化。
DOI：
10.3904/kjim.2015.30.5.580
复制
发表时间：
2015-09
期刊：
影响因子：
--
通讯作者：
Baik SK
中科院分区：
文献类型：
--
作者：
Eom YW;Shim KY;Baik SK
目前，治疗终末期肝纤维化最有效的方法是肝移植;然而，移植受到供体器官短缺、手术并发症、免疫排斥反应和医疗费用高昂的限制。近年来，间充质干细胞（MSC）治疗已被认为是治疗肝脏疾病的有效替代方法。MSC具有分化为肝细胞的潜力，并且治疗价值存在于其免疫调节特性和营养因子（诸如生长因子和细胞因子）的分泌中。此外，间充质干细胞可以抑制炎症反应，减少肝细胞凋亡，增加肝细胞再生，逆转肝纤维化和增强肝脏功能。尽管有这些优点，但问题仍然存在; MSC也具有纤维化潜力和促进肿瘤细胞生长和致癌性的能力。本文就骨髓间充质干细胞的再生医学特性、治疗肝纤维化的机制及临床应用进行综述。我们还提出了几个突出的风险，包括它们的纤维化潜力和促进预先存在的肿瘤细胞生长和致癌性的能力。
Currently, the most effective treatment for end-stage liver fibrosis is liver transplantation; however, transplantation is limited by a shortage of donor organs, surgical complications, immunological rejection, and high medical costs. Recently, mesenchymal stem cell (MSC) therapy has been suggested as an effective alternate approach for the treatment of hepatic diseases. MSCs have the potential to differentiate into hepatocytes, and therapeutic value exists in their immune-modulatory properties and secretion of trophic factors, such as growth factors and cytokines. In addition, MSCs can suppress inflammatory responses, reduce hepatocyte apoptosis, increase hepatocyte regeneration, regress liver fibrosis and enhance liver functionality. Despite these advantages, issues remain; MSCs also have fibrogenic potential and the capacity to promote tumor cell growth and oncogenicity. This paper summarizes the properties of MSCs for regenerative medicine and their therapeutic mechanisms and clinical application in the treatment of liver fibrosis. We also present several outstanding risks, including their fibrogenic potential and their capacity to promote pre-existing tumor cell growth and oncogenicity.